Table 3.
Average survey measure scores for the KOOS subdomains.
| Parameter | Treatment Group | Baseline | 3 Months | 6 Months | 9 Months |
|---|---|---|---|---|---|
| KOOS: ADLs | 20 g/d | 95.9 ± 5.8 | 94.6 ± 7.8 | 96.2 ± 4.7 | 95.6 ± 8.1 |
| Males | 94.5 ± 6.9 | 92.6 ± 9.4 | 94.5 ± 5.5 | 91.8 ± 9.8 | |
| Females | 97.8 ± 3.4 | 97.7 ± 2.7 | 98.5 ± 1.8 | 100.0 ± 0.0 | |
| LF | 95.2 ± 6.7 | 94.9 ± 6.0 | 96.3 ± 5.2 | 95.3 ± 8.1 | |
| HF | 96.4 ± 5.4 | 94.4 ± 9.3 | 96.1 ± 4.5 | 95.8 ± 8.8 | |
| 10 g/d | 92.3 ± 10.1 | 95.0 ± 8.7 | 96.1 ± 6.8L | 93.9 ± 10.3 | |
| Males | 97.5 ± 4.9 | 99.2 ± 1.7 | 97.3 ± 6.0 | 89.1 ± 15.1 | |
| Females | 89.2 ± 11.2 | 92.6 ± 10.3 | 95.5 ± 7.4 | 96.9 ± 4.9*L | |
| LF | 91.5 ± 10.7 | 95.2 ± 6.6 | 95.8 ± 6.3 | 92.9 ± 9.8 | |
| HF | 92.8 ± 10.1 | 94.9 ± 10.3 | 93.7 ± 11.2 | 94.7 ± 11.4 | |
| Placebo | 95.3 ± 7.5 | 95.7 ± 6.6 | 93.9 ± 9.0 | 98.3 ± 3.6 | |
| Males | 93.4 ± 9.3 | 93.6 ± 8.0 | 91.1 ± 10.7 | 97.1 ± 4.7 | |
| Females | 97.9 ± 2.8 | 98.4 ± 2.3 | 97.7 ± 3.8 | 99.8 ± 0.6 | |
| LF | 97.3 ± 4.1 | 97.5 ± 4.6 | 96.9 ± 7.6 | 98.8 ± 3.2 | |
| HF | 93.1 ± 9.8 | 93.7 ± 8.0 | 90.6 ± 9.5 | 97.4 ± 4.5 | |
| KOOS: Pain | 20 g/d | 91.5 ± 8.3 | 90.9 ± 9.2 | 92.8 ± 6.8 | 92.1 ± 11.5 |
| Males | 88.6 ± 8.8 | 88.6 ± 10.1 | 94.5 ± 5.5 | 87.3 ± 14.0 | |
| Females | 95.5 ± 5.7 | 94.4 ± 7.0 | 96.2 ± 4.4 | 97.7 ± 3.7 | |
| LF | 92.0 ± 6.0 | 91.0 ± 8.2 | 92.7 ± 5.5 | 89.8 ± 12.5 | |
| HF | 91.2 ± 9.8 | 90.8 ± 10.4 | 92.9 ± 7.8 | 94.0 ± 11.2 | |
| 10 g/d | 90.9 ± 12.0 | 91.8 ± 9.9 | 92.5 ± 10.8 | 88.7 ± 16.1 | |
| Males | 97.6 ± 5.2 | 95.2 ± 5.2 | 94.0 ± 10.2 | 85.0 ± 19.7 | |
| Females | 87.0 ± 13.3 | 89.8 ± 11.5 | 91.7 ± 11.5 | 91.0 ± 14.4 | |
| LF | 92.4 ± 11.8 | 94.4 ± 5.8 | 91.0 ± 10.8 | 88.4 ± 16.0 | |
| HF | 89.9 ± 10.1 | 89.9 ± 11.9 | 93.7 ± 11.2 | 88.9 ± 17.4L | |
| Placebo | 90.9 ± 11.6 | 88.5 ± 14.7 | 89.2 ± 12.4 | 93.1 ± 10.7 | |
| Males | 87.3 ± 14.0 | 84.0 ± 17.8 | 85.4 ± 13.9 | 89.2 ± 13.5 | |
| Females | 95.7 ± 4.4 | 94.4 ± 5.7 | 87.5 ± 13.6 | 97.6 ± 3.4 | |
| LF | 91.9 ± 14.7 | 90.4 ± 17.9 | 94.2 ± 12.5 | 95.8 ± 7.9 | |
| HF | 89.7 ± 7.4 | 86.4 ± 10.7 | 83.6 ± 10.0 | 87.8 ± 14.4 | |
| KOOS: QOL | 20 g/d | 78.3 ± 17.8 | 80.2 ± 18.6 | 81.9 ± 17.3 | 82.2 ± 15.5 |
| Males | 74.4 ± 21.0 | 80.1 ± 21.8 | 75.6 ± 19.5 | 77.7 ± 19.7 | |
| Females | 83.6 ± 11.5 | 80.4 ± 13.7 | 90.6 ± 8.8 | 87.5 ± 6.8 | |
| LF | 78.9 ± 15.6 | 78.9 ± 24.5 | 82.0 ± 17.8 | 81.3 ± 18.5 | |
| HF | 77.8 ± 20.0 | 81.3 ± 13.5 | 84.5 ± 13.7 | 83.0 ± 13.8 | |
| 10 g/d | 83.2 ± 15.9 | 76.3 ± 19.9 | 84.9 ± 14.9 | 68.8 ± 18.4 | |
| Males | 90.2 ± 11.3 | 83.9 ± 16.9 | 84.8 ± 16.9 | 66.3 ± 25.2 | |
| Females | 79.2 ± 17.1 | 71.9 ± 20.9 | 84.9 ± 14.5 | 70.3 ± 14.5 | |
| LF | 88.3 ± 11.8 | 77.3 ± 23.8 | 84.4 ± 14.9 | 67.7 ± 21.1*L | |
| HF | 79.5 ± 17.9 | 75.6 ± 17.8 | 85.2 ± 15.6 | 69.6 ± 17.5 | |
| Placebo | 81.5 ± 18.2 | 77.4 ± 16.1 | 79.8 ± 18.6 | 81.7 ± 15.8 | |
| Males | 77.1 ± 17.3 | 71.4 ± 16.1 | 74.0 ± 20.3 | 74.2 ± 18.4 | |
| Females | 87.5 ± 18.5 | 85.4 ± 12.9 | 87.5 ± 10.3 | 90.2 ± 4.9 | |
| LF | 88.6 ± 15.5 | 83.0 ± 17.9 | 87.5 ± 18.1 | 86.3 ± 11.7*L | |
| HF | 73.8 ± 18.4 | 71.3 ± 11.9 | 71.3 ± 15.9 | 72.5 ± 20.1 |
All values are reported as means ±SD. KOOS = The Knee Osteoarthritis & Knee Injury Outcome Score, ADLs = activities of daily living, QOL = quality of life, g = grams, d = day. *Denotes p-value < .05, for group by time interaction from mixed model ANOVA using all time points up to the time point denoted. For effect size using partial eta squared (ηp2), Sdenotes small effect size > .01, Mdenotes medium effect size > .06, Ldenotes large effects size > .14, for a significant or trending toward significant (p < .10) group by time interaction from mixed model ANOVA using all time points up to the time point denoted.